Among 29,601 newborns, 23 cases (6 with MMA (5 cblC-MMA, 1 cblA-MMA); 5 with PCD; 3 with PKU; 2 with SCADD; 2 with IBD; 1 with NICCD; 1 with MCAD; 1 with CPTII; 1 with maple syrup urine disease, MSUD; 1 with MADD) of neonatal IEMs involving amino acid, organic acid, or fatty acid metabolism disorders were diagnosed (Table 1). This evidence concerns the gene CPT2 and phenylketonuria.